MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Galectin Therapeutics Company Profile (NASDAQ:GALT)

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.50 (926.79% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetActions
10/30/2015FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015HC WainwrightReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015HC WainwrightInitiated CoverageBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2015MLV & Co.Set Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/1/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014MLV & Co.Lower Price TargetBuy$27.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2014MLV & Co.Boost Price TargetBuy$20.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/11/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha